These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 610314)

  • 1. Hypogonadal men treated with oral testosterone undecanoate.
    Sarris S; Swyer GI; Lawrence DM
    Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A ten-year safety study of the oral androgen testosterone undecanoate.
    Gooren LJ
    J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of testosterone undecanoate in male hypogonadism.
    Maisey NM; Bingham J; Marks V; English J; Chakraborty J
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):625-9. PubMed ID: 7296909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D; Basaria S
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.
    Lanfranco F; Zitzmann M; Simoni M; Nieschlag E
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
    Asscheman H; Gooren LJ
    Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
    Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
    J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone undecanoate: a new orally active androgen.
    Hirschhäuser C; Hopkinson CR; Sturm G; Coert A
    Acta Endocrinol (Copenh); 1975 Sep; 80(1):179-87. PubMed ID: 1098350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
    Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
    Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood.
    Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Gooren L; Ernst M
    Aging Male; 2009 Dec; 12(4):113-8. PubMed ID: 19909203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.